Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1791 results
December 2020
-
Press Release
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase… -
Press Release
Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas
Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1… -
Press Release
Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms1Chronic graft-versus-host disease (GvHD) is a life-threatening… -
Featured News
The Co-Creating Impact Summit for the society and the planet
The Co-Creating Impact Summit happening on December 9th, 2020, will gather experts inside and outside of Novartis to continue our work of improving our impact on the society and the planet.
-
Featured News
Why healthcare’s digital moment is now
-
Featured News
Novartis at ASH
-
In The News
Moving towards the next normal
How changes driven by COVID-19 may shape pharma manufacturing in the long term.
November 2020
-
In The News
Enabling a stable supply of medicines during COVID-19
What are the key factors ensuring Novartis supply chains remain operational during the pandemic? -
Featured News
Meet Novartis Management 2020
Annual meeting highlights progress on the company’s transformation and growth strategy. -
Ad-hoc Release
Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth… -
Story Discovery
New hope for treating inflammatory diseases of the kidney
Novartis researchers aim to preserve kidney function – and quality of life – for patients.
-
Press Release
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other…